Wave Life Sciences presents a high-risk profile, with its financials dominated by extreme revenue volatility from non-recurring licensing events rather than a stable commercial base, as evidenced by quarterly swings from -$7.7M to $83.7M. While the company hol...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$0.34-13.4% vs -$0.30 | $2M-69.5% vs $7M |
Q2 2026 Apr 28, 2026 | -$0.13+61.8% vs -$0.34 | $38M+352.6% vs $8M |
Q1 2026 Feb 26, 2026 | -$0.30-7.1% vs -$0.28 | $17M+7.4% vs $16M |
Q4 2025 Nov 10, 2025 | -$0.32-6.7% vs -$0.30 | $8M-53.5% vs $16M |
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability. Analyst Recommendations This is a summary of
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Benchmark WVE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Wave Life Sciences Ltd. (WVE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.78 | $727.28M | -3.12 | -60.55% | -478.33% | -55.56% | — | |
| $17.50 | $1.85B | -2.45 | 15.58% | -6.93% | -9.96% | — | |
| $43.54 | $7.24B | -18.29 | 33.87% | -64.64% | -110.84% | — | |
| $64.19 | $9.04B | -5261.48 | 23258.15% | -47.79% | -60.05% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — |
Wave Life Sciences Ltd. (WVE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Wave Life Sciences Ltd. (WVE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 26, 2026·SEC
May 18, 2026·SEC
Get notified when WVE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Wave Life Sciences Ltd. (WVE) stock FAQ — growth, dividends, profitability & financials explained
Wave Life Sciences Ltd. (WVE) reported $65.4M in revenue for fiscal year 2025.
Wave Life Sciences Ltd. (WVE) saw revenue decline by 60.5% over the past year.
Wave Life Sciences Ltd. (WVE) reported a net loss of $202.5M for fiscal year 2025.
Wave Life Sciences Ltd. (WVE) has a return on equity (ROE) of -55.6%. Negative ROE indicates the company is unprofitable.
Wave Life Sciences Ltd. (WVE) had negative free cash flow of $186.2M in fiscal year 2025, likely due to heavy capital investments.
